This article explores how digital maturity in process design and parameter management can drive significant time and cost ...

Over the past few months we have heard quite a bit about AI agents and agentic development ... will these common paths be easier to manage and scale, but they should also be easier to diagnose ...

When Genentech licensed experimental drug ... large-scale experiments and we use these experiments in order to understand the biology.'" Executives and industry experts caution that AI adoption ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Article on tech giants' FY25 capex projections and AI data center advances. Nvidia Corporation stock analysis included. Click ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Exscientia will apply both its 'Big Data' resources comprising, among other things, medicinal chemistry and large-scale bio-assays, and its AI-driven ... pre-clinical drug development by using ...